These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31341009)

  • 21. ELP3 stabilizes c-Myc to promote tumorigenesis.
    Zhao W; Ouyang C; Huang C; Zhang J; Xiao Q; Zhang F; Wang H; Lin F; Wang J; Wang Z; Jiang B; Li Q
    J Mol Cell Biol; 2024 Apr; 15(9):. PubMed ID: 37771073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
    Lamant L; Gascoyne RD; Duplantier MM; Armstrong F; Raghab A; Chhanabhai M; Rajcan-Separovic E; Raghab J; Delsol G; Espinos E
    Genes Chromosomes Cancer; 2003 Aug; 37(4):427-32. PubMed ID: 12800156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.
    Raetz EA; Perkins SL; Carlson MA; Schooler KP; Carroll WL; Virshup DM
    Am J Pathol; 2002 Sep; 161(3):875-83. PubMed ID: 12213716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
    Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
    Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
    Armanious H; Gelebart P; Anand M; Lai R
    Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
    Cheng M; Ott GR
    Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ELP3 localises to mitochondria and actin-rich domains at edges of HeLa cells.
    Barton D; Braet F; Marc J; Overall R; Gardiner J
    Neurosci Lett; 2009 May; 455(1):60-4. PubMed ID: 19429107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
    Donella-Deana A; Marin O; Cesaro L; Gunby RH; Ferrarese A; Coluccia AM; Tartari CJ; Mologni L; Scapozza L; Gambacorti-Passerini C; Pinna LA
    Biochemistry; 2005 Jun; 44(23):8533-42. PubMed ID: 15938644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ELP3 controls active zone morphology by acetylating the ELKS family member Bruchpilot.
    Miśkiewicz K; Jose LE; Bento-Abreu A; Fislage M; Taes I; Kasprowicz J; Swerts J; Sigrist S; Versées W; Robberecht W; Verstreken P
    Neuron; 2011 Dec; 72(5):776-88. PubMed ID: 22153374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.
    Bento-Abreu A; Jager G; Swinnen B; Rué L; Hendrickx S; Jones A; Staats KA; Taes I; Eykens C; Nonneman A; Nuyts R; Timmers M; Silva L; Chariot A; Nguyen L; Ravits J; Lemmens R; Cabooter D; Van Den Bosch L; Van Damme P; Al-Chalabi A; Bystrom A; Robberecht W
    Hum Mol Genet; 2018 Apr; 27(7):1276-1289. PubMed ID: 29415125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspergillus fumigatus Elongator complex subunit 3 affects hyphal growth, adhesion and virulence through wobble uridine tRNA modification.
    Zhang Y; Wang Y; Fan J; Zhu G; Lu L
    PLoS Pathog; 2022 Nov; 18(11):e1010976. PubMed ID: 36374932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry.
    Wang P; Wu F; Ma Y; Li L; Lai R; Young LC
    J Biol Chem; 2010 Jan; 285(1):95-103. PubMed ID: 19887368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
    Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
    Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
    Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
    Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.